about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuIdentification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variantsImmune modulation during latent herpesvirus infectionImmune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentCellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyStimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer typesImmunological Evasion in GlioblastomaTargeting microRNAs as key modulators of tumor immune responseThe emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applicationsRole of the tumor microenvironment in mature B-cell lymphoid malignanciesHZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary CarcinogenesisChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsHedgehog signaling: modulation of cancer properies and tumor mircroenvironmentExercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and ProgressionTargeting the indoleamine 2,3-dioxygenase pathway in cancerOverview of current immunotherapeutic strategies for gliomaCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateCurcumin and tumor immune-editing: resurrecting the immune systemPlant-derived immunomodulators: an insight on their preclinical evaluation and clinical trialsThe Evolution of Therapies in Non-Small Cell Lung CancerTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentImmunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsLXR-dependent and -independent effects of oxysterols on immunity and tumor growthThe Yin and Yang of Toll-like receptors in cancerTherapeutic cancer vaccines: past, present, and futureFrom bench to bedside: immunotherapy for prostate cancerBeneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancerAdvances in high-throughput single-cell microtechnologiesChromatin targeting drugs in cancer and immunityHIV infection, aging, and immune function: implications for cancer risk and preventionImmunotherapeutic applications of NK cellsCombining radiotherapy and cancer immunotherapy: a paradigm shiftTargeting regulatory T cells in cancerFunctional Significance of CD57 Expression on Human NK Cells and Relevance to DiseaseThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentThe optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translationOptimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccinesSelective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptorPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
P2860
Q21131200-3FC6D3A1-16AA-48AF-BCA9-C8BDA1DB42D9Q24338843-D18BF52C-04C8-45DE-A604-1A1C7B3F0330Q24624044-51FD2E76-2778-4E01-95DC-C5E77F4A9854Q26738359-80BE6F93-809C-477F-AB90-D26888BD4727Q26745444-418310C4-FF56-419C-95CC-B074C43907D3Q26745894-4C112DD3-DAC0-4BCA-856A-CC5F5C228CE3Q26746612-3917D64A-EA4B-4AFC-8903-09A2429D37DEQ26746972-D6C81623-97FF-4A94-AAD6-F83710A09B45Q26747516-A5BEE0AF-96AB-4E6B-81D0-FD26EFCEB9CCQ26748775-D81C4D56-1606-476C-9A93-4DDE313DE239Q26750868-873C244B-6DCD-4119-8EAF-158AE3F8C06CQ26753082-8A5B96FF-5D77-4506-B22A-9099E6DC316DQ26764740-FC1BBC78-7A7B-4726-A519-36EEA0CAB729Q26775189-F71C057A-DB34-4226-BF8F-B49249264CCEQ26775471-7B843930-6229-4DBA-9262-D91DD1C6FFB0Q26776345-88140D1E-7B46-48D2-8509-0A7777814E24Q26782573-4A7C46BA-0B7F-4A6F-A9F9-57F2FEBA1D0AQ26783491-C4C8A3E1-1BD4-43A9-AB02-E6555927F6EBQ26784434-2B1D6439-4D93-4FD7-905D-F6A51837D45FQ26786932-6E8D2761-61E8-4984-9A01-6743BFB1050EQ26797280-E13558D7-9390-4325-B582-DE517262B4B7Q26799117-F91C6B3E-52D6-42C2-80B8-A2E81F62B478Q26799812-7F95A991-76FC-4864-AA60-54D944FDD662Q26824274-7DE83D1A-EB70-4114-A32A-CBF579007227Q26851526-27A0B298-F71C-43A5-B2D5-32971C010FC6Q26863283-2A1A4E00-6271-4B76-A6C1-6FD97F46E81BQ26864390-2A2BE5AB-352B-4DA0-94A1-0E331778C92FQ26865509-C964F923-B576-4A8B-97FC-12CC8F6E38D3Q26996412-3A6D38C8-90FC-4BAE-8FD0-E22A2F84BDE2Q26999888-F60E084D-A382-4555-85FC-CED07AE21205Q27004165-BFEE06B8-E489-4CBF-B9E6-9372AABDF08DQ27015908-091BE6A7-0440-4058-80C0-F913CF0901ACQ27021428-9521ADE3-63CD-47F0-8510-FC6907DAA181Q27022348-C81D98F5-2511-4F17-B5BA-E0122EF22B74Q27022458-6F0ACED3-168F-4FC8-974F-397EF8200902Q27022789-A95AF676-AEAC-4BEB-87CB-6655A9AE2AB1Q27024106-AFD2ABF7-1F9A-42EB-84A0-340995B37D9DQ27030560-AA8CF0FE-30EF-42BF-9A34-F71250460F91Q27318470-0076F12B-3003-41F4-9934-657D2900273CQ27853353-6D1FC78B-CCAD-40C0-ADA2-568B3E9F9847
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Natural innate and adaptive immunity to cancer
@ast
Natural innate and adaptive immunity to cancer
@en
type
label
Natural innate and adaptive immunity to cancer
@ast
Natural innate and adaptive immunity to cancer
@en
prefLabel
Natural innate and adaptive immunity to cancer
@ast
Natural innate and adaptive immunity to cancer
@en
P2093
P3181
P1476
Natural innate and adaptive immunity to cancer
@en
P2093
Kershaw MH
Schreiber RD
P304
P3181
P356
10.1146/ANNUREV-IMMUNOL-031210-101324
P407
P577
2011-01-01T00:00:00Z